文献速递咽喉与嗓音

围绝经期与绝经后激素替代治疗与嗓音障碍风险:TriNetX研究

Peri- and Post-Menopausal Hormone Replacement Therapy and Voice Disorder Risk: A TriNetX Study.
PubMed 文献 · Laryngoscope · 2026-05-06

本研究基于TriNetX全球协作网络开展回顾性队列研究,纳入40-60岁女性,比较激素替代治疗(HRT)使用者(n=16,586)与非使用者(n=248,725)在倾向性评分匹配后嗓音与共鸣障碍(VRD)及发声困难的风险。结果显示HRT使用者在0-9个月内发声困难风险显著升高(OR 1.72),但1年后无显著差异,总体1年内VRD和发声困难发生率均<0.5%。结论认为HRT对围绝经期及绝经后嗓音无显著临床影响。

要点

  • HRT使用者在0-9个月内发声困难风险升高(OR 1.72),但1年后无显著差异。
  • 两组1年内VRD和发声困难发生率均<0.5%,多数时间点无显著差异。
  • 高BMI的HRT使用者1年VRD发生率与非使用者无显著差异(RD 0.19%,p=0.069)。

核心结论

  • HRT对围绝经期及绝经后嗓音可能无显著临床影响,尽管治疗早期发声困难风险升高,但1年后无显著差异。

研究设计与样本

  • 回顾性队列研究,使用TriNetX全球协作网络,纳入40-60岁女性,HRT使用者n=16,586,非使用者n=248,725,排除头颈部放疗/肿瘤、吸烟、良性喉部病变、甲状腺疾病、性别烦躁及其他系统性激素使用,按年龄、性别、种族和民族进行倾向性评分匹配,每3个月评估VRD和发声困难。

主要发现

  • HRT使用者在0-9个月内发声困难风险显著升高(OR 1.72;95% CI 1.01-2.95),但VRD风险无显著差异(OR 1.66;95% CI 0.99-2.79)。
  • 高BMI的HRT使用者1年VRD发生率与非使用者无显著差异(RD 0.19%,p=0.069)。
  • 两组1年内VRD和发声困难发生率均<0.5%,多数时间点无显著差异。

临床怎么用

  • HRT使用者治疗早期可关注发声困难症状,但长期嗓音风险未见显著增加。

局限性

  • 文献缺乏共识,需未来研究进一步理解HRT对围绝经期及绝经后嗓音的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to elucidate the risk of developing voice disorders among peri- and post-menopausal female hormone replacement therapy (HRT) users. METHODS: A retrospective cohort study was conducted using the TriNetX Global Collaborative Network. Females aged 40-60 years old were included and stratified into two cohorts: HRT users (n = 16,586) and HRT non-users (n = 248,725) while excluding for head and neck radiation/neoplasms, smoking, benign laryngeal lesions, thyroid disorders, gender dysphoria, and any other systemic hormone use. Voice and resonance disorders (VRD) and dysphonia were separately assessed at 3-month intervals post-HRT initiation after propensity score-matching for age, sex, race, and ethnicity. Odds ratios (ORs) with 95% confidence intervals (CIs) and risk differences (RD) were generated to compare outcomes. RESULTS: HRT users had significantly higher odds of dysphonia, but not VRD, within 0-9 months (OR 1.72; 95% CI (1.01-2.95), OR 1.66; 95% CI (0.99-2.79), respectively). For HRT users with elevated BMI, the 1-year VRD incidence was not significantly different than non-HRT users (RD 0.19%, p = 0.069). Overall, the incidence of VRD and dysphonia within 1 year in both groups was < 0.5% and showed no significant difference at most times between groups. CONCLUSIONS: HRT may not have any significant clinical impact on the peri- and post-menopausal voice. Although higher odds were noted earlier after treatment, HRT users did not have higher odds of voice issues after 1 year. This study highlights the lack of consensus in literature and urges future research to fully understand the impact of HRT on peri- and post-menopausal voice.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Kayekjian D, Chun WB, Nguyen SA, et al. Peri- and Post-Menopausal Hormone Replacement Therapy and Voice Disorder Risk: A TriNetX Study. Laryngoscope. 2026. PMID: 42092344. doi:10.1002/lary.70612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。